Medifast (MED) Tops Q3 EPS by 63c, provides guidance

Medifast (NYSE: MED) reported Q3 EPS of $0.35, $0.63 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $140.2 million versus the consensus estimate of $134.15 million.

GUIDANCE:

Medifast sees Q4 2024 EPS of ($0.10)-($0.65), versus the consensus of ($0.14). Medifast sees Q4 2024 revenue of $100-120 million, versus the consensus of $131.7 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Ionic Digital backs Texas data center audit amid grid reliability push